Member Info for Soupdragon78

I preferred foremagnus. At least he didn't tell everyone that nxp004 couldn't possibly be based on Lynparza / Olaparib.

It’s in the past anyway and doesn’t matter.

Reason was Dodgy Daves China contact did a runner after cooking the books in China. Dave sold his shares before telling anyone about it, so had to go.

He then tried to list Ebers on TSX but hasn’t been bothered to follow the regulations so fell flat on his face there.

That said I would expect NXP004 news sooner rather than later.

Mars, given these are half year reports, when they say ‘…by year end’ I’m reading that as by the end of the financial year. (March 31st)

End of sept circa £400k cash in bank and Lanstead paying £20k per month. So at current levels an additional £200k in remaining payments.

And also doesn't help people holding for less than a week, like the person who just sold 902k that they bought on the 6th.

The lanstead deal is of course an albatross around NFX neck.

But the A trades are interesting, especially as they outnumber the shares ever issued as part of the deal and held by Lanstead.

Since February there has been volume of 175.5million shares go through as 'A' trades, whereas only 117.7m were ever issued as part of the deal.

I've given up trying to second guess whether or not, or when something might come.

The Q&A presentation told us they'd shifted to Q1 / 23.

https://erj.ersjournals.com/content/60/suppl_66/2952

In vitro and ex-vivo evaluation of anti-inflammatory and anti-fibrotic effects of NXP002 in rat and human cells and lung tissue

Abstract

Introduction: These studies investigated anti-inflammatory (AI) and anti-fibrotic (AF) effects of NXP002, a new salt form of tranilast and potential novel inhaled treatment for Idiopathic Pulmonary Fibrosis (IPF), in rodent and human cells and lung tissue.

Methods: Freshly isolated rat splenocytes or human peripheral blood mononuclear cells (PBMCs) were incubated with NXP002 (1 to 3000 µM) prior to stimulation with LPS (100 ng/mL). Inflammatory and fibrotic mediators were measured by Luminex multiplex 4 and 24 hours after stimulation.

Precision-cut lung slices (PCLS) were prepared from Sprague Dawley rats. Inflammatory and fibrotic responses were induced with LPS (1µg/ml; 24hrs) or TGF-ß1 + PDGF-ßß (3µg/mL and 50ng/mL; 72hrs). The effects of concomitant administration of NXP002 (75, 150 or 300µM) on inflammatory cytokines, measured by ELISA, and tissue fibrosis marker gene expression by qPCR was assessed. Similar assessments were made in PCLS prepared post transplant from 6 end stage IPF patients.

Results: NXP002 concentration-dependently inhibited LPS-induced cytokine production (IL-6, IL-10, MCP-1) by rat splenocytes and human PBMCs.

In rat PCLS, NXP002 concentration-dependently attenuated LPS induced MCP-1 and dampened IL-6 secretion, and attenuated TGF-ß1 + PDGF-ßß induced upregulation in collagen 1 and aSMA gene expression.

NXP002 demonstrated an AF effect in human IPF tissue, with reduced production of MCP-1, Col1a1 and fibronectin.

Conclusion: NXP002 consistently demonstrated AI and AF effects in rat and human cells and lung tissue. Reductions in key biomarkers of fibrosis in IPF tissue support further evaluation of NXP002 as an inhaled therapy in IPF.

https://erj.ersjournals.com/content/60/suppl_66/2955

Inhaled NXP002 attenuates LPS-induced inflammatory and fibrotic mediator production in the rat lung

Abstract

Introduction: Oral tranilast has been shown to attenuate fibrosis clinically but has limited use due to low bioavailability and systemic side effects. NXP002, a new salt form of tranilast, is a potential novel inhaled treatment for Idiopathic Pulmonary Fibrosis (IPF). These studies assess the distribution, tolerability and efficacy of NXP002 in the rat.

Methods: NXP002 was administered by inhalation (Cirrus 2) to Sprague Dawley rats at target lung deposited doses of 0.1, 0.3 and 1 mg/rat. NXP002 (10 mg/kg) was also dosed orally. Inhaled Fluticasone propionate (FP, target 0.3 mg/rat) acted as a positive control. Animals were then challenged with aerosolized LPS (1 mg/mL).

Animals were culled 4 h post LPS challenge and blood samples taken. Bronchoalveolar Lavage (BAL) was obtained, centrifuged and the supernatant collected for bioanalysis, cell counting and mediator determination. NXP002 levels in plasma and lung ****genate were determined.

Results: Inhaled NXP002 was well tolerated, with no inflammatory response observed. Dose-dependent increases of NXP002 in lung tissue and BAL were observed, equivalent to or higher than following oral administration despite lower plasma levels.

Inhaled NXP002 resulted in a dose-dependent decrease in LPS-induced BAL cell count, which was less than that seen following oral delivery. Despite this, inhaled delivery resulted in a greater reduction in LPS-induced BAL mediators, including MCP-1 and TGFß.

Conclusions: This study demonstrates that inhaled NXP002 is well tolerated. Inhaled delivery has a superior effect on fibrosis related mediators whilst having a reduced systemic exposure than oral dosing.

It’s so bad blood ninja won’t sell because he’s afraid it will go up after he does.

Maybe the chairman is the person who signs off such an rns.

Gilbert leads the audit committee on the nfx board, so probs why his name is on the rns.

It’s no biggie. The regulations for auditors have changed and as of today they need to be registered for PIE work. Jeffrey’s have chosen not to be registered that’s all, so can’t audit the company.

Most PIE firms are audited by the big four, PwC, Deloitte, KPMG and EY.

Looks like Dodgy Dave Tapolczay’s Ebers Tech has had a management change after failing to submit their accounts for three years running.
Top lads

ssshhh... its sleepy time.

lol. $2m up front payment from AZ to C4XD! For worldwide rights! Makes Oxilio look like big spenders!

Who says nothing has happened?